2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Dihydropyrimidine Dehydrogenase (DPD)

Dihydropyrimidine Dehydrogenase (DPD)

Dihydropyrimidine Dehydrogenase

Dihydropyrimidine Dehydrogenase (DPD) is a pyrimidine catabolic enzyme that catalyzes the two-electron reduction of pyrimidine bases uracil and thymine. Dihydropyrimidine dehydrogenase catalyzes the first step of pyrimidine catabolism by promoting the reduction of the 5,6-vinylic bond of thymine or uracil with electrons acquired from NADPH. Mammalian Dihydropyrimidine dehydrogenase is a functional homodimer and each subunit contains an FAD, an FMN and four Fe4S4 centers with two Fe4S4 centers from each subunit forming an electron transfer conduit that link the flavins within each subunit. Dihydropyrimidine dehydrogenase accepts the pervasive chemotherapeutic 5-Fluorouracil as a substrate, severely shortening its pharmacological half-life and dictating the use of elaborate compensatory administration protocols to achieve efficacious toxicity[1].

Dihydropyrimidine Dehydrogenase (DPD) Related Products (6):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-17469
    Gimeracil
    		99.81%
    Gimeracil, a component of an oral fluoropyrimidine derivative S-1, inhibits DNA DSB repair and is a potent inhibitor of DPYD (dihydropyrimidine dehydrogenase, DPD).
    Gimeracil
  • HY-W001983
    5-Iodouracil
    		Inhibitor 99.95%
    5-Iodouracil (Compound 4b) is an irreversible dihydropyrimidine dehydrogenase (DPD) inhibitor (IC50=0.22 μM). 5-Iodouracil is promising for research of DPD-overexpressing solid tumors like non-small cell lung cancer (NSCLC).
    5-Iodouracil
  • HY-19413
    Ro-09-4889
    		Inhibitor
    Ro-09-4889 is a prodrug. Ro-09-4889 can inhibit dihydropyrimidine dehydrogenase (DPD) activity and its effect is dose-dependent. Ro-09-4889 can be used for cancer research.
    Ro-09-4889
  • HY-114249
    DFP-11207
    		Inhibitor
    DFP-11207 is an orally active fluoropyrimidine cytotoxic agent. DFP-11207 combines a 5-FU (HY-90006) pro-drug with a reversible DPD inhibitor and a potent inhibitor of OPRT, resulting in enhanced pharmacological activity of 5-FU with decreased gastrointestinal and myelosuppressive toxicities. DFP-11207 can be used for the research of cancer .
    DFP-11207
  • HY-W777340
    Gimeracil-13C3
    Gimeracil-13C3 (Gimestat-13C3) is the 13C-labeled Gimeracil (HY-17469). Gimeracil, a component of an oral fluoropyrimidine derivative S-1, inhibits DNA DSB repair and is a potent inhibitor of DPYD (dihydropyrimidine dehydrogenase, DPD).
    Gimeracil-<sup>13</sup>C<sub>3</sub>
  • HY-17469R
    Gimeracil (Standard)
    Gimeracil (Standard) is the analytical standard of Gimeracil. This product is intended for research and analytical applications. Gimeracil, a component of an oral fluoropyrimidine derivative S-1, inhibits DNA DSB repair and is a potent inhibitor of DPYD (dihydropyrimidine dehydrogenase, DPD).
    Gimeracil (Standard)